NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 903.3 DKK | -1.05% |
|
+2.28% | +29.39% |
| 10:18pm | US Equity Markets Close Mixed Monday After Fed Officials' Remarks | MT |
| 10:05pm | Novo Nordisk's Wegovy May Be More Effective for Patients With Specific Genes, Study Shows | MT |
Presenter SpeechGöran Ando (Executives)And welcome to the 2016 Annual General Meeting of Novo ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.39% | 58TCr | |
| +34.35% | 69TCr | |
| -3.49% | 37TCr | |
| +20.15% | 33TCr | |
| +6.19% | 29TCr | |
| +14.11% | 24TCr | |
| -3.03% | 21TCr | |
| +10.02% | 21TCr | |
| +9.21% | 17TCr | |
| -0.90% | 16TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Transcript : Novo Nordisk A/S - Shareholder/Analyst Call
